What was the overall market valuation for the US herpes zoster market in 2024?

The overall market valuation for the US herpes zoster market was $55.12 Million in 2024. Read More

What is the projected market valuation for the US herpes zoster market by 2035?

The projected market valuation for the US herpes zoster market is $100.0 Million by 2035. Read More

What is the expected CAGR for the US herpes zoster market during the forecast period 2025 - 2035?

The expected CAGR for the US herpes zoster market during the forecast period 2025 - 2035 is 5.56%. Read More

Which companies are considered key players in the US herpes zoster market?

Key players in the US herpes zoster market include GSK, Merck & Co, Pfizer, Sanofi, AstraZeneca, Bristol-Myers Squibb, Novartis, and Teva Pharmaceutical Industries. Read More

What were the revenue figures for antiviral medications in the treatment segment in 2024?

In 2024, the revenue figures for antiviral medications in the treatment segment ranged from $10.0 Million to $18.0 Million. Read More

How much revenue did vaccines generate in the treatment and prevention segment in 2024?

Vaccines generated revenue between $28.12 Million and $50.0 Million in the treatment and prevention segment in 2024. Read More

What is the revenue range for oral administration in the route of administration segment in 2024?

The revenue range for oral administration in the route of administration segment was between $20.0 Million and $35.0 Million in 2024. Read More

What were the revenue figures for hospitals and clinics as end users in 2024?

In 2024, hospitals and clinics as end users generated revenue between $20.0 Million and $35.0 Million. Read More

What is the expected growth trend for the US herpes zoster market in the coming years?

The US herpes zoster market is expected to grow steadily, with a projected valuation of $100.0 Million by 2035. Read More

What segment generated the highest revenue in the diagnosis category in 2024?

In 2024, serological testing generated the highest revenue in the diagnosis category, ranging from $15.0 Million to $25.0 Million. Read More

US Herpes Zoster Market

US Herpes Zoster Market Research Report By End User (Hospitals & Clinics, Diagnostic Centers, Research & Academic Institutes, Home Care Settings, Others) By Diagnosis (Laboratory Testing, Immunofluorescent Microscopy, Real-Time Polymerase Chain Reaction (PCR), Serological Testing, Others) By Route of Administration (Oral, Topical, Others) By Treatment and Prevention (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Capsaicin, Numbing Creams, Gels, or Patches, Vaccines, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.56%

2024 Market Size

$ 55.12 Million

2035 Market Size

$ 100 Million

Healthcare ● Updated January 2026 Report ID: MRFR/HC/16521-CR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Diagnosis (USD Million)
  1. 4.1.1 Laboratory Testing
  2. 4.1.2 Immunofluorescent Microscopy
  3. 4.1.3 Real-Time Polymerase Chain Reaction (PCR)
  4. 4.1.4 Serological Testing
  5. 4.1.5 Others
2. 4.2 Pharmaceutical, BY Treatment and Prevention (USD Million)
  1. 4.2.1 Antiviral Medications
  2. 4.2.2 Narcotic Medications
  3. 4.2.3 Anti-Inflammatory Medications
  4. 4.2.4 Antihistamines
  5. 4.2.5 Anticonvulsants
  6. 4.2.6 Capsaicin
  7. 4.2.7 Numbing Creams, Gels, or Patches
  8. 4.2.8 Vaccines
  9. 4.2.9 Others
3. 4.3 Pharmaceutical, BY Route of Administration (USD Million)
  1. 4.3.1 Oral
  2. 4.3.2 Topical
  3. 4.3.3 Others
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Diagnostic Centers
  3. 4.4.3 Research & Academic Institutes
  4. 4.4.4 Home Care Settings
  5. 4.4.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 GSK (GB)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Bristol-Myers Squibb (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT AND PREVENTION
4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY DIAGNOSIS, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TREATMENT AND PREVENTION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TREATMENT AND PREVENTION, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT AND PREVENTION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Herpes Zoster Market Segmentation

US Herpes Zoster Market By Diagnosis (USD Million, 2025-2035)

Laboratory Testing
Immunofluorescent Microscopy
Real-Time Polymerase Chain Reaction (PCR)
Serological Testing
Others

US Herpes Zoster Market By Treatment and Prevention (USD Million, 2025-2035)

Antiviral Medications
Narcotic Medications
Anti-Inflammatory Medications
Antihistamines
Anticonvulsants
Capsaicin
Numbing Creams, Gels, or Patches
Vaccines
Others

US Herpes Zoster Market By Route of Administration (USD Million, 2025-2035)

Oral
Topical
Others

US Herpes Zoster Market By End User (USD Million, 2025-2035)

Hospitals & Clinics
Diagnostic Centers
Research & Academic Institutes
Home Care Settings
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”